Aine Miller's most recent trade in Theravance Biopharma Inc was a trade of 6,989 Ordinary Shares done at an average price of $13.4 . Disclosure was reported to the exchange on Aug. 20, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Theravance Biopharma Inc | Aine Miller | SVP, DEV & HEAD OF IRE OFFICE | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.39 per share. | 20 Aug 2025 | 6,989 | 208,001 (0%) | 0% | 13.4 | 93,583 | Ordinary Shares |
| Theravance Biopharma Inc | Aine Miller | SVP, DEV & HEAD OF IRE OFFICE | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2025 | 10,430 | 224,691 (0%) | 0% | 0 | Ordinary Shares | |
| Theravance Biopharma Inc | Aine Miller | SVP, DEV & HEAD OF IRE OFFICE | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.45 per share. | 19 May 2025 | 9,701 | 214,990 (0%) | 0% | 9.4 | 91,674 | Ordinary Shares |
| Theravance Biopharma Inc | Aine Miller | SVP, DEV & HEAD OF IRE OFFICE | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 75,000 | 214,261 (0%) | 0% | 0 | Ordinary Shares | |
| Theravance Biopharma Inc | Aine Miller | SVP, DEV & HEAD OF IRE OFFICE | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.66 per share. | 20 Feb 2025 | 11,295 | 139,261 (0%) | 0% | 9.7 | 109,110 | Ordinary Shares |
| Theravance Biopharma Inc | Aine Miller | SVP, DEV & HEAD OF IRE OFFICE | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.97 per share. | 20 Nov 2024 | 10,076 | 150,556 (0%) | 0% | 10.0 | 100,458 | Ordinary Shares |
| Theravance Biopharma Inc | Aine Miller | SVP, DEV & HEAD OF IRE OFFICE | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.22 per share. | 20 Aug 2024 | 5,201 | 160,632 (0%) | 0% | 8.2 | 42,752 | Ordinary Shares |
| Theravance Biopharma Inc | Aine Miller | SVP, DEV & HEAD OF IRE OFFICE | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.10 per share. | 20 May 2024 | 5,201 | 165,833 (0%) | 0% | 9.1 | 47,329 | Ordinary Shares |
| Theravance Biopharma Inc | Aine Miller | SVP, DEV & HEAD OF IRE OFFICE | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2024 | 37,500 | 171,034 (0%) | 0% | 0 | Ordinary Shares | |
| Theravance Biopharma Inc | Aine Miller | SVP, DEV & HEAD OF IRE OFFICE | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.92 per share. | 20 Feb 2024 | 11,782 | 133,534 (0%) | 0% | 8.9 | 105,095 | Ordinary Shares |